Inotuzumab
As of the edition of 20 October 2026, Inotuzumab is an antibody: marketed, first approved in 2017 (CH); acts on CD22.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Antibody
- Brand name
- Besponsa
- First approved
- 10 July 2017 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Registered trials
- 1, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD22 | B-cell receptor CD22 | P20273 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 2017 to now |